rTMS + Virtual Reality Therapy for Mild Cognitive Impairment
(rTMS+iVCT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether combining brain stimulation with virtual reality training can improve thinking abilities and mood in older adults with Mild Cognitive Impairment (MCI). Participants will be divided into groups: one receiving only brain stimulation using rTMS (a non-invasive method that uses magnetic fields to stimulate the brain), another receiving both rTMS and virtual reality cognitive exercises, and a control group with no intervention. It targets individuals diagnosed with MCI, aged 55 or older, who meet specific cognitive criteria. As an unphased trial, this study offers participants a unique opportunity to contribute to innovative research that could enhance cognitive health in older adults.
Will I have to stop taking my current medications?
The trial requires that you stop taking medications known to increase the risk of seizures and ototoxic medications (medications that can damage the ear). If you are on these medications, you may need to stop them to participate.
What prior data suggests that this combination of rTMS and iVCT is safe for individuals with Mild Cognitive Impairment?
Research has shown that repetitive Transcranial Magnetic Stimulation (rTMS) is generally safe for people with Mild Cognitive Impairment (MCI). Studies indicate that rTMS is usually well-tolerated, with serious side effects being rare. Most people experience only minor issues, such as headaches or a tingling sensation on the scalp.
The combination of rTMS with immersive virtual reality cognitive training (iVCT) remains under study. Early research suggests it is safe, but more studies are needed for confirmation. Overall, current evidence on rTMS, especially when used alone, is promising for safety. For those considering joining this study, it appears to be a low-risk option based on current research.12345Why are researchers excited about this trial?
Researchers are excited about rTMS combined with Virtual Reality Therapy for Mild Cognitive Impairment because it offers a novel, non-invasive approach to brain stimulation that might enhance cognitive function. Unlike traditional medications like cholinesterase inhibitors or memantine, which can have side effects and focus on slowing cognitive decline, rTMS uses magnetic fields to stimulate nerve cells in the brain, potentially improving memory and thinking skills. The addition of immersive Virtual Reality Therapy could further engage and challenge the brain in ways that standard therapies cannot, providing a dual-action approach that both stimulates and exercises cognitive pathways. This combination could offer a promising alternative for those who don't respond well to current treatments.
What evidence suggests that this trial's treatments could be effective for Mild Cognitive Impairment?
Studies have shown that repetitive Transcranial Magnetic Stimulation (rTMS) can improve thinking and memory in people with Mild Cognitive Impairment (MCI). Specifically, research indicates that rTMS led to noticeable improvements in memory and cognitive test scores. In this trial, one group will receive rTMS treatment alone, while another group will receive a combination of rTMS and Virtual Reality cognitive training (iVCT). Early findings suggest that combining rTMS with iVCT might further enhance thinking skills. Using rTMS and virtual reality together has improved memory and other cognitive abilities. Overall, these treatments show promise for boosting brain function in those with MCI.15678
Are You a Good Fit for This Trial?
This trial is for adults over 55 with Mild Cognitive Impairment (MCI) who score at least 18 on the MoCA test. It's not suitable for those with implanted devices, under 55, seizure risks, history of certain neurological issues, or sensitivity to light and sound.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo baseline assessment to evaluate cognitive, emotional, and functional abilities
Treatment
Participants receive rTMS or rTMS+iVCT treatment for 5 days a week for 2 weeks
Post-treatment Assessment
Participants repeat testing to assess treatment-related changes
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- iVCT
- rTMS
rTMS is already approved in United States, European Union for the following indications:
- Obsessive-Compulsive Disorder (OCD)
- Major Depressive Disorder
- Migraines
- Smoking cessation
- Obsessive-Compulsive Disorder (OCD)
- Major Depressive Disorder
Find a Clinic Near You
Who Is Running the Clinical Trial?
Central Arkansas Veterans Healthcare System
Lead Sponsor